Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

17.69
-0.0700-0.39%
Post-market: 17.860.1700+0.96%18:15 EDT
Volume:2.13M
Turnover:37.65M
Market Cap:2.22B
PE:-9.85
High:18.09
Open:17.85
Low:17.46
Close:17.76
Loading ...

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Zacks
·
02 Apr

Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

MT Newswires Live
·
01 Apr

Apellis Pharmaceuticals Inc - Pdufa Target Action Date for Empaveli Is July 28, 2025

THOMSON REUTERS
·
01 Apr

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli® (Pegcetacoplan) for C3g and Primary Ic-Mpgn

THOMSON REUTERS
·
01 Apr

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

GlobeNewswire
·
01 Apr

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Evercore ISI Remains a Buy on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
24 Mar

U.S. RESEARCH ROUNDUP-American Electric Power, Block, Lenz Therapeutics

Reuters
·
18 Mar

Apellis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $45 From $54

THOMSON REUTERS
·
18 Mar

Apellis Pharmaceuticals (APLS) Gets a Hold from Mizuho Securities

TIPRANKS
·
07 Mar

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Benzinga
·
06 Mar

UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating

MT Newswires Live
·
05 Mar

Stock Track | Apellis Pharmaceuticals Soars 5.07% as JP Morgan Maintains Overweight Rating

Stock Track
·
05 Mar

Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

Zacks
·
03 Mar

Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush

Dow Jones
·
03 Mar

Apellis Pharmaceuticals Inc : Wedbush Cuts Target Price to $29 From $30

THOMSON REUTERS
·
03 Mar

Apellis Pharmaceuticals (APLS) Receives a Hold from Scotiabank

TIPRANKS
·
03 Mar

Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

RBC Trims Price Target on Apellis Pharmaceuticals to $25 From $26, Keeps Sector Perform Rating

MT Newswires Live
·
03 Mar